Pharmacokinetics/Pharmacodynamics

Jochberger S, Mayr V, Luckner G, et al. Antifactor Xa

activity in critically ill patients receiving antithrombotic

prophylaxis with standard dosages of certoparin: a pro-

https://doi.org/10.1186/cc3792

Johnston JD, Harvey CJ, Menzies IS, Treacher DF.

Gastrointestinal permeability and absorptive capacity in

org/10.1097/00003246-199607000-00013

Joukhadar C, Frossard M, Mayer BX, et al. Impaired

target site penetration of beta-lactams may account

for therapeutic failure in patients with septic shock.

Crit

Care

Med.

2001;29(2):385-391.

https://doi.

org/10.1097/00003246-200102000-00030

Karaba SM, Cosgrove SE, Lee JH, et al. Extended-

infusion β-lactam therapy, mortality, and subsequent

antibiotic resistance among hospitalized adults with

Open.

2024;7(7):e2418234.

https://doi.org/10.1001/

jamanetworkopen.2024.18234

Khwaja A. KDIGO clinical practice guidelines for acute

kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184.

https://doi.org/10.1159/000339789

Kirwan CJ, MacPhee IA, Lee T, Holt DW, Philips

BJ. Acute kidney injury reduces the hepatic metabo-

lism of midazolam in critically ill patients. Intensive

s00134-011-2360-8

Kiser TH, Mann AM, Trujillo TC, Hassell KL.

Evaluation of empiric versus nomogram-based direct

thrombin inhibitor management in patients with sus-

Hematol. 2011;86(3):267-272. https://doi.org/10.1002/

ajh.21955

Klem C, Dasta JF, Reilley TE, Flancbaum LJ.

Variability

in

dobutamine

pharmacokinet-

ics in unstable critically ill surgical patients. Crit

Care

Med.

1994;22(12):1926-1932.

https://jour-

nals.lww.com/ccmjournal/abstract/1994/22120/

variability_in_dobutamine_pharmacokinetics_in.7.aspx

Knights KM, Rowland A, Miners JO. Renal drug

metabolism in humans: the potential for drug-endo-

biotic interactions involving cytochrome P450 (CYP)

and UDP-glucuronosyltransferase (UGT). Br J Clin

Pharmacol. 2013;76(4):587-602. https://doi.org/10.1111/

bcp.12086

Kramer HJ, Jaar BG, Choi MJ, et al. An endorse-

ment of the removal of race from GFR estimation

equations: a position statement from the National

Kidney Foundation Kidney Disease Outcomes Quality

doi.org/10.1053/j.ajkd.2022.08.004

Kruger PS, Freir NM, Venkatesh B, Robertson TA,

Roberts MS, Jones M. A preliminary study of atorvas-

tatin plasma concentrations in critically ill patients with

doi.org/10.1007/s00134-008-1358-3

Lahner E, Annibale B, Delle Fave G. Systematic

review: impaired drug absorption related to the co-

administration

of

antisecretory

therapy.

Aliment

Pharmacol Ther. 2009;29(12):1219-1229. https://doi.

org/10.1111/j.1365-2036.2009.03993.x

Lauzier F, Lévy B, Lamarre P, Lesur O. Vasopressin

or norepinephrine in early hyperdynamic septic

Med.

2006;32(11):1782-1789.

https://doi.org/10.1007/

s00134-006-0378-0

Lebrault C, Duvaldestin P, Henzel D, Chauvin M,

Guesnon P. Pharmacokinetics and pharmacodynamics

of vecuronium in patients with cholestasis. Br J Anaesth.

1986;58(9):983-987. https://doi.org/10.1093/bja/58.9.983

Lemaitre F, Hasni N, Leprince P, et al. Propofol, mid-

azolam, vancomycin and cyclosporine therapeutic drug

monitoring in extracorporeal membrane oxygenation

2015;19(1):40. https://doi.org/10.1186/s13054-015-0772-5

Mahmood SS, Pinsky MR. Heart-lung interactions dur-

2018;6(18):349. https://doi.org/10.21037/atm.2018.04.29

Martin C, Eon B, Saux P, Aknin P, Gouin F. Renal

effects of norepinephrine used to treat septic shock

org/10.1097/00003246-199003000-00007

Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug

dosing consideration in patients with acute and chronic

kidney disease—a clinical update from Kidney Disease:

Improving

Global

Outcomes

(KDIGO).

Kidney

Int.

2011;80(11):1122-1137.

https://doi.org/10.1038/

ki.2011.322

McKindley DS, Boucher BA, Hess MM, Rodman JH,

Feler C, Fabian TC. Effect of acute phase response